《Table 2 Status of Treponema pallidum A2058G and A2059G mutations in azithromycin-or BPG-treated pat
本系列图表出处文件名:随高清版一同展现
《Relationship between the high frequency of 23S rRNA point mutations in Treponema pallidum and low serological response rate to azithromycin treatment in China》
Chi-squared tests were conducted,and P-values of<0.05 wereconsidered to indicate statistical significance.BPG,benzathinepenicillin G.
The A2058G and A2059G mutation statuses in the azithromycin and BPG groups are shown in Table 2.Of the 89 DNA samples obtained from the azithromycin group that were positive for the tpp47 gene,83(93.3%)were positive for a mutation,including 71(79.8%)positive for A2058G and 12(20.2%)positive for A2059G.Of these 83 samples,51(61.4%)were collected from chancres and 32 from condyloma lata and mucosal lesions.Of the 98 equivalent samples obtained from the BPG group,89(90.8%)were positive for one of the two mutations;82(83.7%)of these 89 patients had an A2058G mutation,and 7(7.1%)had an A2059G mutation.There was no significant difference in the proportions of the two mutations between the azithromycin and BPG groups(P>0.05).
图表编号 | XD0051435200 严禁用于非法目的 |
---|---|
绘制时间 | 2019.03.01 |
作者 | Rui-Li Zhang、Qian-Qiu Wang、Zhi-Ju Zheng、Guo-Jun Liang、Li-Jia Yang、Li-Gang Yang、Dong-Nu Pei、Shao-Chun Lin |
绘制单位 | Department of Dermatology, Affiliated Wuxi No.2 People’s Hospital of Nanjing Medical University、National Center for STD Control and Prevention, China Centers for Diseases Control and Prevention,Hospital for Skin Diseases (Institute of Dermatology), Chines |
更多格式 | 高清、无水印(增值服务) |
查看“Table 2 Status of Treponema pallidum A2058G and A2059G mutations in azithromycin-or BPG-treated patients”的人还看了
- Table 1.The current status of coupled models and coupled assimilation in world modeling and prediction centers applied i
- Table 2 Correlation between total circulating tumor cell status and clinicopathological factors of patients with pancrea
- Table 4 Correlation between total circulating tumor cell status and clinicopathological factors of patients with pancrea